High-dose Antioxidants for Central Serous Chorioretinopathy

Overview

Central serous chorioretinopathy (CSC) is the serous neurosensory detachment that usually involves the macular area. It is common in patients between 30-50 years old and effects male more often than female with the ratio of 5-10. The common risk factors are psychologic stress, type A personality, systemic steroid use, hypertension and pregnancy. The treatment is usually observation especially in the first three-months. The laser or photodynamic therapy should be considered when the condition does not improve after that time. Nevertheless, the pathogenesis of CSC is still not well understood but the study from indocyanine green angiography showed the choroidal vascular hyperpermeability and abnormal leakage. The causes of this abnormality are supposed to be from nitric oxide, prostaglandins or even free oxidative radicals. From this hypothesis, the oxidative process might be involved in the pathogenesis of the disease especially in the early stage. This study is to determine the effect of antioxidants drugs in the acute stage of CSC and to determine whether they can improve the outcomes of the disease.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 2008

Interventions

  • Drug: antioxidants tablets
    • vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.

Arms, Groups and Cohorts

  • Experimental: antioxidant tablets
    • the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
  • Placebo Comparator: placebo tablets
    • the control arm received placebo tablets for 3 months or until the resolution of the disease

Clinical Trial Outcome Measures

Primary Measures

  • visual acuity and central macular thickness
    • Time Frame: 6 months

Secondary Measures

  • fluorescein leakage at the third month
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

1. patients with acute central serous chorioretinopathy within 6 weeks of onset 2. age between 30-50 years 3. new or recurrent attack (the symptom-free period should longer than 6 months) 4. fluorescein angiography (FA) confirmed the diagnosis with the inkblot or smoke-stack leakage and the optical coherence tomography (OCT) showed definite subretinal fluid 5. patients' ability for proper follow up. Exclusion Criteria:

1. chronic central serous chorioretinopathy(longer than 6 weeks) 2. complicated central serous chorioretinopathy such as secondary choroidal neovascularization (CNV) that detected from FA 3. pregnancy, steroid user and patients that contraindicated for high dose antioxidants therapy such as heavy smokers, lung cancer, thyrotoxicosis, renal stone and anemia (hematocrit less than 30%).

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Prince of Songkla University
  • Collaborator
    • Alcon Research
  • Provider of Information About this Clinical Study
    • Associated professor Mansing Ratanasukon, MD, Department of Ophthalmology, Faculty of medicine, Prince of Songkla university
  • Overall Official(s)
    • Mansing – Ratnasukon, MD, Principal Investigator, Department of Ophthalmology, Faculty of medicine, Prince of Songkla university, Hat yai, Songkhla province, Thailand 90110

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.